{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:50:44Z","timestamp":1759798244229,"version":"build-2065373602"},"posted":{"date-parts":[[2025,7,1]]},"group-title":"In Review","reference-count":39,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,6,21]]},"abstract":"<title>Abstract<\/title>\n        <p><bold>Background<\/bold>\nPeople with HIV (PWH) are at increased risk of stroke likely due to many factors including antiretroviral therapy (ART). We sought to evaluate the association between ARTand risk of stroke in PWH.\n<bold>Methods<\/bold>\nWe conducted a prospective case-control study at the University Teaching Hospital in Lusaka, Zambia between March 2022 and October 2024 in PWH comparing those with stroke (cases) and without (controls) matched (1:2) for age, sex and race. Standardized data collection instruments were used to collect demographic, clinical, laboratory and imaging information. Comparisons were made between the cases and controls, and subgroup analysis by ART duration was done for the cases.\n<bold>Results<\/bold>\nWe analyzed results for 205 cases and 410 controls. Compared to controls, cases were more likely to have hypertension (71% vs. 18%, <italic>p<\/italic>=0.001), lower CD4 counts [293(163-592) cells\/\u00b5l vs. 533 (376-688) cells\/\u00b5l, <italic>p<\/italic>=0.0001] and to be on second line ART (23% vs. 4%, <italic>p<\/italic>=0.001). Hypertension (aOR 19.7, 95% CI 3.1-126.4, <italic>p<\/italic>=0.002) and Tenofovir Disoproxil Fumarate (TDF) use (aOR 85.3, 95% CI 5.3-1380.7, <italic>p<\/italic>=0.002) were associated with increased odds of stroke, whereas Dolutegravir (aOR 0.03, 95% CI 0.001-0.58, <italic>p<\/italic>=0.02) and alcohol use (aOR 0.24, 95% CI 0.06-0.95) were associated with reduced odds of stroke. The majority of stroke patients on long-term ART were using Dolutegravir (80% vs. 35%, <italic>p<\/italic>=0.001) and TDF (72% vs. 42%, <italic>p<\/italic>=0.01).\n<bold>Conclusion<\/bold>\nIn PWH, TDF associates with higher odds of stroke. Although Dolutegravir associates with reduced odds of stroke, stroke patients on long-term ART are more likely to be on it.<\/p>","DOI":"10.21203\/rs.3.rs-6945551\/v1","type":"posted-content","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T06:48:27Z","timestamp":1751352507000},"source":"Crossref","is-referenced-by-count":0,"title":["Antiretroviral Therapy and Risk of Stroke in People with HIV in Zambia"],"prefix":"10.21203","author":[{"given":"Stanley","family":"ZIMBA","sequence":"first","affiliation":[{"name":"University Teaching Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Owen","family":"NGALAMIKA","sequence":"additional","affiliation":[{"name":"University of Zambia School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"MUKAMBO","sequence":"additional","affiliation":[{"name":"University Teaching Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"SHANKANGA","sequence":"additional","affiliation":[{"name":"University Teaching Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taonga","family":"MSIMUKO","sequence":"additional","affiliation":[{"name":"University Teaching Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diwell","family":"MWANSA","sequence":"additional","affiliation":[{"name":"University Teaching Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bwalya","family":"MULENGA","sequence":"additional","affiliation":[{"name":"University Teaching Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"CHISHA","sequence":"additional","affiliation":[{"name":"University Teaching Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mashina","family":"CHOMBA","sequence":"additional","affiliation":[{"name":"University of Zambia School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melody","family":"ASUKILE","sequence":"additional","affiliation":[{"name":"University Teaching Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorraine","family":"CHISHIMBA","sequence":"additional","affiliation":[{"name":"University Teaching Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Violet","family":"KAYAMBA","sequence":"additional","affiliation":[{"name":"University of Zambia School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lloyd","family":"MULENGA","sequence":"additional","affiliation":[{"name":"University Teaching Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"SIDDIQI","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Harvard Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Owen A.","family":"ROSS","sequence":"additional","affiliation":[{"name":"Mayo Clinic College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masharip","family":"ATADZHANOV","sequence":"additional","affiliation":[{"name":"University Teaching Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deanna","family":"SAYLOR","sequence":"additional","affiliation":[{"name":"University Teaching Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","volume-title":"HIV: fact sheet on Sustainable Development Goals (SDGs): health targets: World Health Organization","author":"Organization WH","year":"2017","unstructured":"Organization WH. HIV: fact sheet on Sustainable Development Goals (SDGs): health targets: World Health Organization. Regional Office for Europe; 2017."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1747-4949.2006.00064.x","article-title":"The neglected burden of stroke in Sub-Saharan Africa","volume":"1","author":"Kengne AP","year":"2006","unstructured":"Kengne AP, Anderson CS. The neglected burden of stroke in Sub-Saharan Africa. Int J Stroke. 2006;1:180\u201390.","journal-title":"Int J Stroke"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(16)31460-X","article-title":"Global, regional, and national disability-adjusted life years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990\u20102015: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors (GBD) 2015 Study","volume":"388","author":"Uthman OA","year":"2016","unstructured":"Uthman OA. Global, regional, and national disability-adjusted life years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990\u20102015: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors (GBD) 2015 Study. Lancet. 2016;388:1603\u201358.","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1136\/jnnp.2007.116103","article-title":"Stroke in patients with human immunodeficiency virus infection","volume":"78","author":"Tipping B","year":"2007","unstructured":"Tipping B, de Villiers L, Wainwright H, Candy S, Bryer A. Stroke in patients with human immunodeficiency virus infection. J Neurol Neurosurg Psychiatry. 2007;78:1320\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1097\/QAD.0000000000002999","article-title":"Risk factors and outcomes of HIV-associated stroke in Zambia","volume":"35","author":"Zimba S","year":"2021","unstructured":"Zimba S, Nutakki A, Chishimba L, et al. Risk factors and outcomes of HIV-associated stroke in Zambia. Aids. 2021;35:2149\u201355.","journal-title":"Aids"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/QAI.0b013e31825c7f24","article-title":"Comparison of ischemic stroke incidence in HIV-infected and non\u2013HIV-infected patients in a US health care system","volume":"60","author":"Chow FC","year":"2012","unstructured":"Chow FC, Regan S, Feske S, Meigs JB, Grinspoon SK, Triant VA. Comparison of ischemic stroke incidence in HIV-infected and non\u2013HIV-infected patients in a US health care system. JAIDS J Acquir Immune Defic Syndr. 2012;60:351\u20138.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S1474-4422(12)70205-3","article-title":"HIV infection and stroke: current perspectives and future directions","volume":"11","author":"Benjamin LA","year":"2012","unstructured":"Benjamin LA, Bryer A, Emsley HC, Khoo S, Solomon T, Connor MD. HIV infection and stroke: current perspectives and future directions. Lancet Neurol. 2012;11:878\u201390.","journal-title":"Lancet Neurol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/EDE.0000000000001331","article-title":"HIV viremia and risk of stroke among people living with HIV who are using antiretroviral therapy","volume":"32","author":"Harding BN","year":"2021","unstructured":"Harding BN, Avoundjian T, Heckbert SR, et al. HIV viremia and risk of stroke among people living with HIV who are using antiretroviral therapy. Epidemiology. 2021;32:457\u201364.","journal-title":"Epidemiology"},{"key":"ref9","first-page":"1291","article-title":"Stroke in patients with human immunodeficiency virus infection","author":"Connor M","year":"2007","unstructured":"Connor M. Stroke in patients with human immunodeficiency virus infection. BMJ Publishing Group Ltd, 2007: 1291\u20131291.","journal-title":"BMJ Publishing Group Ltd"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/infdis\/jix340","article-title":"The role of human immunodeficiency virus\u2013associated vasculopathy in the etiology of stroke","volume":"216","author":"Benjamin LA","year":"2017","unstructured":"Benjamin LA, Allain TJ, Mzinganjira H, et al. The role of human immunodeficiency virus\u2013associated vasculopathy in the etiology of stroke. J Infect Dis. 2017;216:545\u201353.","journal-title":"J Infect Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/HJR.0b013e328336a150","article-title":"Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study","volume":"17","author":"Friis-M\u00f8ller N","year":"2010","unstructured":"Friis-M\u00f8ller N, Thiebaut R, Reiss P, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev rehabilitation. 2010;17:491\u2013501.","journal-title":"Eur J Cardiovasc Prev rehabilitation"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/cid\/civ296","article-title":"The lipid-lowering effect of tenofovir\/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial","volume":"61","author":"Santos JR","year":"2015","unstructured":"Santos JR, Saumoy M, Curran A, et al. The lipid-lowering effect of tenofovir\/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial. Clin Infect Dis. 2015;61:403\u20138.","journal-title":"Clin Infect Dis"},{"year":"2020","author":"Huhn GD","key":"ref13","unstructured":"Huhn GD, Shamblaw DJ, Baril J-G et al. Atherosclerotic cardiovascular disease risk profile of tenofovir alafenamide versus tenofovir disoproxil fumarate. Open forum infectious diseases; 2020: Oxford University Press US: ofz472."},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","article-title":"Class of antiretroviral drugs and the risk of myocardial infarction","volume":"356","author":"Group DS","year":"2007","unstructured":"Group DS. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723\u201335.","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1212\/WNL.0000000000002278","article-title":"HIV, antiretroviral treatment, hypertension, and stroke in Malawian adults: a case-control study","volume":"86","author":"Benjamin LA","year":"2016","unstructured":"Benjamin LA, Corbett EL, Connor MD, et al. HIV, antiretroviral treatment, hypertension, and stroke in Malawian adults: a case-control study. Neurology. 2016;86:324\u201333.","journal-title":"Neurology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1177\/0049475520953704","article-title":"Immune reconstitution inflammatory syndrome: a report of TB-IRIS after switching from efavirenz to dolutegravir","volume":"51","author":"Zimba S","year":"2021","unstructured":"Zimba S, Mbewe N, Chishimba L, Chomba M, Saylor D. Immune reconstitution inflammatory syndrome: a report of TB-IRIS after switching from efavirenz to dolutegravir. Trop Doct. 2021;51:216\u20138.","journal-title":"Trop Doct"},{"year":"2014","author":"Walmsley S","key":"ref17","unstructured":"Walmsley S, Berenguer J, Khuong-Josses M, Kilby J, Lutz T, Podzamczer D. Dolutegravir regimen statistically superior to efavirenz\/tenofovir\/emtricitabine: 96-week results from the SINGLE study (ING114467). Conference on Retrovirues and Opportunistic Infections; 2014."},{"key":"ref18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/QAD.0000000000000519","article-title":"Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials","volume":"29","author":"Raffi F","year":"2015","unstructured":"Raffi F, Rachlis A, Brinson C, et al. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials. Aids. 2015;29:167\u201374.","journal-title":"Aids"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12981-016-0115-x","article-title":"Dolutegravir (DTG, S\/GSK1349572) combined with other ARTs is superior to RAL-or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials","volume":"13","author":"Jiang J","year":"2016","unstructured":"Jiang J, Xu X, Guo W, et al. Dolutegravir (DTG, S\/GSK1349572) combined with other ARTs is superior to RAL-or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials. AIDS Res therapy. 2016;13:1\u201310.","journal-title":"AIDS Res therapy"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1161\/01.STR.25.11.2220","article-title":"Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group","volume":"25","author":"Lyden P","year":"1994","unstructured":"Lyden P, Brott T, Tilley B, et al. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke. 1994;25:2220\u20136.","journal-title":"Stroke"},{"year":"2008","author":"Scale S","key":"ref21","unstructured":"Scale S. Modified Rankin Scale. http:\/\/www strokecenter org\/trials\/scales\/rankin html. 2008."},{"key":"ref22","first-page":"1983","article-title":"World Health Organization, International Society of Hypertension Writing Group","volume":"21","author":"Whitworth J","year":"2003","unstructured":"Whitworth J. World Health Organization, International Society of Hypertension Writing Group. J Hypertens. 2003;21:1983\u201392.","journal-title":"J Hypertens"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation","volume":"15","author":"Alberti KGMM","year":"1998","unstructured":"Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med. 1998;15:539\u201353.","journal-title":"Diabet Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pop.2012.11.003","article-title":"Hyperlipidemia as a risk factor for cardiovascular disease","volume":"40","author":"Nelson RH","year":"2012","unstructured":"Nelson RH. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2012;40:195.","journal-title":"Prim Care"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/0140-6736(91)93206-O","article-title":"Classification and natural history of clinically identifiable subtypes of cerebral infarction","volume":"337","author":"Bamford J","year":"1991","unstructured":"Bamford J, Sandercock P, Dennis M, Warlow C, Burn J. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991;337:1521\u20136.","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris PA","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.","journal-title":"J Biomed Inform"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris PA","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377\u201381.","journal-title":"J Biomed Inform"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12981-021-00383-7","article-title":"Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States","volume":"18","author":"Dorjee K","year":"2021","unstructured":"Dorjee K, Desai M, Choden T, Baxi SM, Hubbard AE, Reingold AL. Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States. AIDS Res therapy. 2021;18:1\u201310.","journal-title":"AIDS Res therapy"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial","volume":"292","author":"Gallant JE","year":"2004","unstructured":"Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191\u2013201.","journal-title":"JAMA"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12872-025-04833-2","article-title":"Characterization and stratification of risk factors of stroke in people living with HIV: A theory-informed systematic review","volume":"25","author":"Nweke M","year":"2025","unstructured":"Nweke M, Mshunqane N. Characterization and stratification of risk factors of stroke in people living with HIV: A theory-informed systematic review. BMC Cardiovasc Disord. 2025;25:1\u201334.","journal-title":"BMC Cardiovasc Disord"},{"year":"2017","author":"Wijting I","key":"ref31","unstructured":"Wijting I, Rokx C, Wit F, Postma A, Hoepelman A, van der Ende M. Integrase Inhibitors are an Independent Risk Factor for IRIS: an ATHENA-Cohort Study. Conference on Retroviruses and Opportunistic Infections; 2017: 13\u201316."},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2174\/1381612823666170329142059","article-title":"Recent advances in antiretroviral agents: potent integrase inhibitors","volume":"23","author":"Psichogiou M","year":"2017","unstructured":"Psichogiou M, Poulakou G, Basoulis D, Paraskevis D, Markogiannakis A, Daikos L. Recent advances in antiretroviral agents: potent integrase inhibitors. Curr Pharm Design. 2017;23:2552\u201367.","journal-title":"Curr Pharm Design"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3390\/v16091462","article-title":"Comparative Effects of Efavirenz and Dolutegravir on Metabolomic and Inflammatory Profiles, and Platelet Activation of People Living with HIV: A Pilot Study","volume":"16","author":"Roux CG","year":"2024","unstructured":"Roux CG, Mason S, du Toit LD, Nel J-G, Rossouw TM, Steel HC. Comparative Effects of Efavirenz and Dolutegravir on Metabolomic and Inflammatory Profiles, and Platelet Activation of People Living with HIV: A Pilot Study. Viruses. 2024;16:1462.","journal-title":"Viruses"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1016\/S2352-3018(23)00328-4","article-title":"Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts","volume":"11","author":"Byonanebye DM","year":"2024","unstructured":"Byonanebye DM, Polizzotto MN, Maltez F, et al. Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts. Lancet HIV. 2024;11:e321\u201332.","journal-title":"Lancet HIV"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/0956462417732226","article-title":"Association between the use of protease inhibitors in highly active antiretroviral therapy and incidence of diabetes mellitus and\/or metabolic syndrome in HIV-infected patients: A systematic review and meta-analysis","volume":"29","author":"Echecopar-Sabogal J","year":"2018","unstructured":"Echecopar-Sabogal J, D\u2019Angelo-Piaggio L, Chanam\u00e9-Baca DM, Ugarte-Gil C. Association between the use of protease inhibitors in highly active antiretroviral therapy and incidence of diabetes mellitus and\/or metabolic syndrome in HIV-infected patients: A systematic review and meta-analysis. Int J STD AIDS. 2018;29:443\u201352.","journal-title":"Int J STD AIDS"},{"year":"2024","author":"Parra-Rodriguez L","key":"ref36","unstructured":"Parra-Rodriguez L, Sahrmann JM, Butler AM, Olsen MA, Powderly WG, O\u2019Halloran JA. Antiretroviral Therapy and Cardiovascular Risk in People With HIV in the United States\u2014An Updated Analysis. Open Forum Infectious Diseases; 2024: Oxford University Press US: ofae485."},{"key":"ref37","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1212\/WNL.0000000000201388","article-title":"Alcohol intake as a risk factor for acute stroke: the INTERSTROKE study","volume":"100","author":"Smyth A","year":"2023","unstructured":"Smyth A, O'Donnell M, Rangarajan S, et al. Alcohol intake as a risk factor for acute stroke: the INTERSTROKE study. Neurology. 2023;100:e142\u201353.","journal-title":"Neurology"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1001\/jama.289.5.579","article-title":"Alcohol consumption and risk of stroke: a meta-analysis","volume":"289","author":"Reynolds K","year":"2003","unstructured":"Reynolds K, Lewis B, Nolen JDL, Kinney GL, Sathya B, He J. Alcohol consumption and risk of stroke: a meta-analysis. JAMA. 2003;289:579\u201388.","journal-title":"JAMA"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ijcard.2014.04.225","article-title":"Alcohol intake and risk of stroke: a dose\u2013response meta-analysis of prospective studies","volume":"174","author":"Zhang C","year":"2014","unstructured":"Zhang C, Qin Y-Y, Chen Q, et al. Alcohol intake and risk of stroke: a dose\u2013response meta-analysis of prospective studies. Int J Cardiol. 2014;174:669\u201377.","journal-title":"Int J Cardiol"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6945551\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6945551\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T16:12:39Z","timestamp":1759767159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6945551\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":39,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-6945551\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1186\/s12981-025-00799-5","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2025,7,1]]},"subtype":"preprint"}}